Taken together, RNLS should be considered in the analysis of BCR-ABL1-related mechanisms in the development and maintenance of CML, as well as management strategies that aim to overcome TKI resistance and CML progression. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.